Wada et al. used a well-described genetically engineered mouse, autochronous prostate cancer model to explore the relative sequencing and dosing of anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody when combined with a cell-based, granulocyte macrophage colony-stimulating factor- (GM-CSF-) secreting vaccine [124]. The gene discussed is CSF2; the disease is Familial prostate cancer.